Skip to main content

1218-0091 A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 24 weeks, with a double-blind active treatment safety extension period to 52 weeks, in children and ad

NCT03429543

A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 24 weeks, with a double-blind active treatment safety extension period to 52 weeks, in children and adolescents with type 2 diabetes mellitus

Associated Conditions

Diabetes Type 2

Principal Investigator

Sponsor

Boehringer Ingelheim Pharmaceuticals

This study is being done to: (a) compare the safety and effects of the study drugs, called empagliflozin and linagliptin with a placebo, in children and adolescents with type 2 diabetes, during the first 25 weeks of this study. A placebo looks like the study drugs but has no drug in it; and (b) continue to compare the safety of empagliflozin and linagliptin for an additional 26 weeks once all subjects are assigned to receive the active study drugs.

This study is currently enrolling.